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Abstract
Background: Acinetobacter baumannii causes frequently nosocomial infections worldwide. Its ability to survive on
dry surfaces facilitates its spread and the persistence of endemic situations, especially in the intensive care units
(ICUs).
The objective of this paper is to describe a multicomponent intervention program designed to control a
hyperendemic persistence of multidrug-resistant A. baumannii (MDR-Ab) and to characterize its impact.
Methods: Design: Quasi-experimental intervention study based on open cohorts.
Setting: Public tertiary referral centre. Period: January 2009–August 2017.
Intervention: multifaceted program based on environmental decontamination, hand hygiene, antimicrobial
stewardship, contact precautions, active surveillance, weekly reports and regular meetings.
Analysis: joinpoint regression and interrupted time-series analysis.
Results: The intervention was successfully implemented. Through the study period, the compliance with contact
precautions changed from 0 to 100% and with hand hygiene, from 41.8 to 82.3%. Between 2012 and 2016, the
antibiotic consumption decreased from 165.35 in to 150.44 daily-defined doses/1000 patients-days in the ICU. The
incidence density of MDR-Ab in the ICU was 10.9 cases/1000 patients-days at the beginning of the intervention.
After this moment, the evolution of the incidence density of MDR-Ab was: between months 0 and 6°, it remained
stable; between months 7° and 10°: there was an intense decrease, with an average monthly percentage change
(AMPC) = − 30.05%; from 11° month until the end, the decrease was lighter but continuous (AMPC:-2.77%),
achieving an incidence density of 0 cases/1000 patients-days on the 18° month, without any new case for 12
months. From the 30° month until the end of the study period, several little outbreaks of MDR-Ab were detected,
all of them rapidly controlled. The strains of MDR-Ab isolated during these outbreaks were not clonally related with
the previously endemic one, which supports its eradication from the environmental reservoirs.
Conclusion: The multicomponent intervention performed by a multidisciplinary team was effective to eradicate the
endemic MDR-Ab.
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Background
Acinetobacter baumannii is a frequent etiology of
nosocomial infections worldwide, posing a major challenge
due to its great ability to develop resistance against antibi-
otics [1, 2]. In recent years, most reported clinical isolates
are multidrug-resistant, and several outbreaks caused by
extremely-drug resistant (XDR) or even pan-drug resistant
(PDR) have been described [3–5]. Hospital outbreaks and
endemic situations are expedited by the capacity of A. bau-
mannii to survive on all kind of surfaces [6]. However, al-
though some outbreaks could be controlled by eliminating
an environmental reservoir [7], in many centres all over the
world affected by endemic situations with occasional super-
imposed outbreaks [8–11], endemicity tipically persists after
controlling the outbreaks flaring up. This problem affects
especially to Intensive Care Units (ICUs) [2, 12].
Our hospital experienced a two decades-long hyperen-
demic situation with A. baumannii and even an out-
break of PDR-A. baumannii in 2002 [5]. Since 2008,
most clinical isolates were carbapenem-resistant, all of
them susceptible to colistin. Despite several interven-
tions, including hand hygiene, contact precautions and
an antimicrobial stewardship program, the incidence of
multidrug resistant A. baumannii (MDR-Ab) did not de-
crease. In late 2012, a second outbreak of XDR-A. bau-
mannii-resistant to colistin was declared in the adults
ICU.
After the epidemiological investigation and environmen-
tal and surveillance cultures, a molecular characterization
of the XDR isolates by pulsed-field gel electrophoresis
(PFGE) [13] confirmed that they were closely related, ac-
cording to the Tenover criteria [14]. With the purpose of
facing this situation, we designed an alternative interven-
tional program to control the outbreak and the endemic
situation. On this paper, we report the multicomponent
program developed and its impact on the incidence of
MDR-Ab.
Methods
Setting
University Hospital Virgen del Rocío (Seville, Spain) is a
1367 bed-centre with two adult ICUs, which have six
multibed open wards for medical and surgical patients
(50 beds), and two wards for trauma and neurosciences
areas divided into rooms for one patient each (18 beds).
This is a reference centre for severe trauma, neurosur-
gery, burn patients and solid organ and bone marrow
transplantations. During the studied period, the hospital
and ICUs had, respectively, an average of 52,593 and
3379 inpatient episodes per year.
Study design
This is a quasi-experimental intervention study, based on
open cohorts of all the patients admitted to the hospital
from the 1st January 2009 to the 31stAugust 2017, having
a pre-intervention period of 46months and a post-
intervention period of 58months.
Infection control team
A multidisciplinary team, composed of an infection con-
trol and hospital hygiene specialist, a microbiologist, a
pharmaceutical specialist, an infectious diseases phys-
ician and three nurses with expertise in infection con-
trol, designed and led the intervention program.
Intervention program
A multifaceted program was implemented. All the mea-
sures agreed the current recommendations of the
Centers for Disease Control and Prevention (CDC) [15].
Environmental decontamination
An exhaustive environmental cleaning policy was insti-
tuted. The disinfectant used were a hypochlorite-based
disinfectants; for the handling of not-disposable medical
products in which this disinfectant was not appropriate,
a wipe disinfectant containing benzalkonium chloride
and propane-1,2-diol was used. Medical products were
exclusive of each colonized of infected patient. Dispos-
able medical products were discarded once the patient
did not need them any more following the CDC recom-
mendations [16], and not-disposable products were
cleaned following the procedures previously described.
To verify the environmental decontamination proced-
ure, two specific checklists were created: one for the
general environmental cleaning and the other for med-
ical equipment disinfection. These checklists had to be
filled by the cleaning staff every time that any cleaning
procedure was performed, and at least twice each day;
the percentage of compliance was monitored weekly.
The infection control team met several times with the
cleaning staff for educational purposes and feedback of
the results.
Every ICU ward was sequentially closed for a terminal
cleaning at the beginning of the program, and periodic-
ally at least thrice a year. Afterwards, every bedside of
the ICU and the rooms in other wards from which a col-
onized patient was discharged underwent terminal
cleaning as well.
Hand hygiene instruction and surveillance
Hand hygiene education courses were provided to the ICU
staff the first weeks after the XDR-Ab outbreak, and period-
ically afterwards, emphasizing on training on newly incor-
porated staff. The hand hygiene training was based on the
performance of periodic workshops in which the five mo-
ments for hand hygiene were remembered and the tech-
nique was trained using an UV glow box. During the first
year, structured observation of hand hygiene compliance
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during the daily care activity was performed weekly by the
nurses of the infection control team in the ICU, following
the recommendations and observation tool of the WHO
[17]. Afterwards, this observation was performed periodic-
ally (at least once each month). The percentage of compli-
ance was included in the weekly reports.
Antimicrobial stewardship program
Until the outbreak of XDR-Ab was controlled, colistin
was restricted, needing pre-authorization and being re-
vised the indication and duration of every colistin
course. Afterwards, the educational stewardship program
previously set in the hospital [18] was enhanced in the
ICUs, adding a weekly feedback of the antibiotic con-
sumption data to the staff.
Isolation and contact precautions
Contact precautions, following the CDC recommenda-
tions [16], were already mandatory for patients carrying
MDR-Ab. In addition, we implemented the surveillance
of its compliance and displayed information posters in
every affected unit.
Contact precautions were maintained through the
whole admission period for patients with MDR-Ab.
Active surveillance for MDR-Ab colonization
All patients admitted to adult ICUs were screened
weekly. Surveillance cultures were obtained by rectal
and pharyngeal swabs.
Weekly report
A weekly report was made with the evolution of the se-
lected indicators. It includes the level of compliance of
the measures and the results achieved. Definitions and
indicators are described below.
Regular meetings with the staff of the affected areas
The infection control team met weekly with the staff of
the ICUs (physicians, nurses, assistant nurses, hospital
attendants, housekeepers) to discuss the results of the
weekly report, and to take additional measures when ne-
cessary. Additionally, the medical and nurse directors
were informed by weekly email for the whole period.
Definitions and indicators
A. baumannii was defined as MDR or XDR following the
criteria of Magiorakos et al. [19], which consider that A.
baumannii is MDR when non-susceptible to ≥1 agent in
≥3 antimicrobial categories (including aminoglycosides, car-
bapenems, fluorquinolones, antipseudomonal penicillins+β-
lactamases inhibitors, extended spectrum cephalosporins,
trimethoprim-sulphamethoxazole, ampicillin-sulbactam,
polymixins and tetracyclines) and XDR when non-
susceptible to ≥1 agent in all but ≤2 of the same categories.
If the susceptibility to one antimicrobial was not tested, it
was classified as “resistant” (see below). The main outcome
was the incidence density of MDR-Ab in clinical samples,
defined as the number of patients newly infected or colo-
nized with MDR-Ab per 1000 patient-days. Surveillance
samples were excluded because of their absence in the pre-
intervention period. An isolate of MDR-Ab was considered
as a new episode after 365 days of the last positive culture
in the same patient or when the initial infection was cured
and MDR-Ab was not isolated in three rectal swabs per-
formed in three consecutive weeks. Hand hygiene compli-
ance was expressed as the percentage of correct actions
over all the observed ones [20]. The appropriateness of the
isolation and contact precautions was evaluated with a form
designed for this purpose. The global compliance was the
percentage of patients with a correct response to all the
items over the total of patients under contact precautions
observed. Environmental and medical equipment cleaning
compliance was evaluated by checklists designed for this
purpose, completed by the responsible staff (housekeepers
and assistant nurses, respectively). They were stated as the
percentage of correct actions of each item over the total.
Antimicrobial consumption was measured in Daily Defined
Doses (DDD) per 1000 patients-days. Hand hygiene, con-
tact precautions and cleaning compliance were surveyed
just in the ICUs; all the others in the whole hospital, analys-
ing separately the ICUs.
Microbiological procedures
Active surveillance for MDR-Ab colonization was
performed in all patients admitted to the ICU with
at least prior 48 h hospitalization [21]. The culture
media used was Brilliance™ CRE Agar, a chromo-
genic screening plate for the detection of
carbapenem-resistant strains with high sensitivity
and specificity and whose results are available in just
18–24 h. Each isolate was identified by the Matrix-
assisted laser desorption/ionization time of flight
mass spectrometry (MALDI-TOF MS- Brucker®).
Susceptibility testing to colistin and meropenem of
the isolates was studied by E-test© (AB Biodisk,
Sweden) according to the manufacturer’s recommen-
dations. Susceptibility to other antibiotics was per-
formed by using commercial microdilution methods
(PMicroScan combo NC58. BeckamCoulter. USA).
Amikacin, ampicillin/sulbactam, imipenem, minocy-
cline and tigecycline were tested in all the isolates.
Due to the generalized resistance to some groups of
antibiotics (fluorquinolones, antipseudomonal peni-
cillins+β-lactamases inhibitors, extended spectrum
cephalosporins, trimethoprim-sulphamethoxazole and
tetracycline) among the isolates of A. baumannii
from our hospital in previous years, the susceptibility
to them was tested just in a variable proportion of
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isolates. The breakpoints used were those recom-
mended by EUCAST in each time frame [22].
Molecular typing using PFEG was performed for the ini-
tial outbreak investigation, as mentioned above, and to the
new isolates of the outbreaks that occurred after the eradi-
cation of the endemic. Plug preparation, lysis, cell wash-
ing, restriction digestion (60 U of ApaI), and
electrophoresis were performed as previously described
[13]. PFGE was performed by using a clamped homoge-
neous electric field electrophoresis (CHEF) DRIII appar-
atus (Bio-Rad Laboratories, Hercules, CA). The conditions
employed were as follows: temperature of 14 °C, voltage of
6 V/cm, run time of 19 h, and switch time of 5 to 20 s.
The images obtained were processed with Bio- Rad Mo-
lecular Imager® GelDoc™ XR+ with Lab™ Software. PFGE
clustering was determined by using the unweighted-pair
group method with arithmetic averages (UPGMA) and by
using Dice’s coefficient. The tolerance was set at 1%. All
calculations were performed by using InfoQuest software
(Applied Maths, Saint-Martens-Latem, Belgium). The re-
sults of the PFGE typing were compared according to the
Tenover criteria [14].
Statistical analysis
To estimate changes in the observed trends we used a
joinpoint regression analysis [23], with previous evalu-
ation of homocedasticity and existence of autocorrel-
ation for each variable using SPSS Version 19.0
(Armonk, NY: IBM Corp.). These models give a double
result: they identify the time point in which the trend
changes and they also estimate the observed trend in
each time interval. A maximum of three turning points
were searched for each regression analysis. Statistical sig-
nificance was set in an alpha error of 0.05. The software
used was Joinpoint Regression Program, Version 4.5.0.1
- June 2017 (Statistical Methodology and Applications
Branch, Surveillance Research Program, National Cancer
Institute, Bethesda, MD, USA). In addition, we per-
formed an interrupted time series (ITS) analysis with R
version 3.4.3.
Results
Rates of MDR-Ab colonization and infection
The outbreak of XDR-Ab affected five patients and was
controlled in three weeks. The incidence density of MDR-
Ab was 10.9 cases/1000 patients-days at the beginning of
the enhanced infection control program. The monthly
tracking of this incidence is represented in Fig. 1. Sixty
weeks after the multifaceted program started, the inci-
dence achieved 0 cases/patients-days in the ICUs. No new
cases were described for 34 weeks since week 94. Later,
there have been several outbreaks after the eradication of
the endemic situation, caused by patients previously colo-
nized at the moment of the admission (Fig. 1). On Fig. 2,
PFGE shows the restriction profiles of genomes extracted
from isolates causing outbreaks occurred in 2015 and
compares to those caused in 2009. The differences on
bands that are observed among the lanes indicate that the
isolates causing these outbreaks were distinct from those
of the preceding years at level of their genomes, applying
Tenover criteria [14].
The incidence density of MDR-Ab bacteraemia at the
beginning of the program was 0.026 cases/1000 patients-
days, with a crude mortality of 50%. Three trimesters
later, the incidence achieved 0.000 cases/1000 patients-
days and no new cases of MDR-Ab bacteraemia have
been observed.
The joinpoint regression analysis of the MDR-Ab rates
is given in Table 1. This analysis selected the beginning
of the multifaceted intervention as the point of trend
change, either in the wards or the ICU (Fig. 3). In the
ICU there was an upward baseline trend (AMPC:
0.23%); 6 months after the intervention (month 52) we
observed a trend change followed by an intense decrease
during four months (AMPC: − 30.05%), continuing with
a significant tendency towards zero (AMPC: − 2.77%)
until the end of the period. In the rest of adult wards the
AMPC underwent a change prior to the implementation
of the program in month 34 (1.07%), followed by a pro-
longed decline (AMPC: − 4.02%) maintained for 18
months, moving to a final trend not statistically signifi-
cant (AMPC: 3,94%).
For the interrupted time series analysis, we consid-
ered a 6-month lag to reach endemic control (time
necessary to decrease the incidence density rates of
5‰). In the ICU we observed an increasing baseline
trend followed, after the phase-in period, by a de-
creasing non-linear trend throughout the rest of the
period (Fig. 4).
Environmental decontamination
The first weeks, the overall environmental cleaning
compliance was 83%. After 14 weeks, a 100% of com-
pliance in all the items of the checklists was
achieved.
Contact precautions and hand hygiene
The first evaluation revealed that the adherence to all
the indicated measures of contact precautions was
correct in 0% of the cases. Although all the colo-
nized/infected patients were visibly identified, the in-
dividual protection equipment was correctly located
just in 5.6% of them and only 22.2% received the ap-
propriate hygiene, while the visits policy was system-
atically incorrect. Two years later, the compliance
with the contact precautions was 100% in all the eval-
uated items.
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The compliance with the hand hygiene was 41.8%
in the first surveillance campaign. Until October
2014, after 702 observations, the average rate of
hand hygiene adherence had been 82.3%. Nonethe-
less, adherence rates have been varying throughout
the study period and are closely related to changes
in the staff.
Surveillance cultures
During the study period, between 80 and 100 weekly
samples were processed and 169 patients were colo-
nized by MDR-Ab. The incidence of newly colo-
nized patients decreased along with the isolation of
MDR-Ab from clinical samples, as shown in Fig. 1.
From 31/12/2016 to 31/08/2017, no cases of
Fig. 1 Evolution of the incidence density rates of multidrug resistant A. baumannii: a) the whole hospital; b) the adults intensive care units
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nosocomial acquisition of MDR-Ab were detected
by surveillance cultures.
Antibiotic consumption
The antibiotics consumption decreased during the study
period, as we previously reported [24]. The global antibiotic
consumption in the ICU decreased from 165.35 DDD/1000
to 150.44 DDD/1000 patients-days between 2012 and 2016,
while the consumption of colistin reduced from 25.96 to
6.65 DDD/patients-days during the same period. The con-
sumption of carbepenems also decreased notably (from
31.47 to 15.9 DDD/1000 patients-days), with moderate in-
crease of families with less spectrum of activity, as penicil-
lins, penicillins/β-lactamase inhibitors and cephalosporins.
(Evolution of the consumption of diverse antimicrobials in
the ICUs from the beginning of the whole intervention to
the end of the study is shown in Additional file 1).
Discussion
A two-decade intense endemic setting of MDR-Ab can
be eradicated. To achieve this success, we needed a
long-term multifaceted program, led by a
Fig. 2 PFGE profiles of ApaI-digested genomic DNA from clinical and environmental strains of A. baumannii
Table 1 Changes in rates of multidrug resistant Acinetobacter baumannii infection and colonization: results from the joinpoint
regression analysis
Settings Incidence Rates MDR-Ab
Pre-intervention trend Point of change 1 Post 1 trend Point of change 2 Post 2 trend
AMPC [CI95%]
(p-value)
Month [CI95%]
p < 0.05
AMPC [CI95%]
(p-value)
Month [CI95%]
p < 0.05
AMPC [CI95%] (p-value)
Adults hospital (ICU + wards) 0.21%[−0.40;0.82]
(p = 0.50)
49 [41;54]
(Jan/2013)
−12.14% [−17.48;-6.46]
(p = 0.001]
67 [53;84] (Jul/2014) 0.46 [−4.05;5.18] (p = 0.84)
ICU 0.23%[−0.25;0.71]
(p = 0.34)
52 [50;54]
(Apr/2013)
−30.05%[−55.10;8.98]
(p = 0.11)
56 [54;67]
(Aug/2013)
−2,77% [−4.91;-0.57]
(p = 0.01)
Adults wards 1.07% [0.01;2.13]
(p = 0.05)
34 [30;50]
(Oct/2011)
−4.02% [−5.37;-2.65]
(p = 0.001)
84 [61;95]
(Dec/2015)
3.94 [−2.40;10.70] (0.23)
AMPC Average monthly percentage change, CI confidence interval, MDR-Ab multidrug resistant Acinetobacter baumannii, ICU intensive care unit
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multidisciplinary infection-control team, and involving
the hospital management and all the concerned staff.
The efficacy of this kind of approaches is widely
supported by previous reports [25–32], with small dif-
ferences among them in the measures registered,
adapted to the local particularities. Many authors
have reported a complete control of MDR-Ab out-
breaks in hospitals where this rod was not previously
present [28, 30–32], and many others described the
efficacy of infection control programs to significantly
reduce the incidence of MDR-Ab in centres with
long-term endemic situations [25, 26, 29]. Moreover,
a PDR-Ab outbreak was successfully controlled in
2002–03 by a multicomponent approach in our hos-
pital, but it was unable to reach a complete eradica-
tion of MDR-Ab [5].
Fig. 3 Joinpoint regression analysis of the incidence density of multidrug resistant A. baumannii: a) the adult wards; b) the adult intensive
care units
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Furthermore the multifaceted approach, currently
mandatory, there were several aspects that probably en-
abled these results.
First of all, there is the “human factor”, that must be
considered as the essential element on the multifaceted
program: a strong formation on antimicrobial stewardship
and infection disease management is required, with the
necessary knowledge about how to lead the intervention;
the unconditional institutional support from the Medical
Director and Director of Nurses of both the hospital and
the affected units; and also to keep the meetings with the
staff, either for education or feedback.
Secondly, the relevance of keeping the actions along
the time. Despite all the efforts, we needed 6months to
control the endemic situation, 60 weeks to appreciate an
improvement on the incidence of MDR-Ab and 94
weeks to maintain these results. The persistence of res-
ervoirs (colonized patients, environmental sources) and
the lack of compliance of hand hygiene or contact pre-
cautions can explain this discouraging phenomenon, de-
scribed in most successfully controlled MDR-Ab
endemic situations [25]. Thus, infection control teams
that want to face these situations may be aware: immedi-
ate effects are not expectable, and achieving successful
significant results with multifaceted programs needs a
long implementation period. A relevant impact will
probably appear after several months of keeping to the
measures and with periodical evaluation of possible er-
rors of compliance. In addition, the occurrence of out-
breaks of MDR-Ab after the eradication of the endemic
situation, caused either by community patients previ-
ously colonized or patients transferred from other hospi-
tals is almost warranted; which is another reason to
maintain the continuance of the program.
The bundle applied was big and complex, but many of
its measures were on going previously. Why were not they
working until the whole bundle began? Likely due to the
addition of two crucial measures: compliance assessment
and surveillance cultures with periodic feedback. To
understand the relevance of the first, it should be
reminded that initial observations revealed that contact
precautions and hand hygiene were being poorly accom-
plished. Educational meetings with those responsible for
environmental cleaning, the development of checklists
and the direct surveillance of hand hygiene and contact
precaution accomplishment started in a context of profes-
sional and institutional requirement. We opted for direct
observation and checklists because of their educational
Fig. 4 Interrupted time series analysis with transition 6-month period of the incidence density of multidrug resistant A. baumannii in the intensive
care units
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effect among the several methods described to assessment
processes of infection control [33].
The performance of surveillance cultures is part of
most programs for the control of MDR-Ab [25–27,
29, 30, 32], supported by a moderate level of evidence
[33]. The European Society of Clinical Microbiology
and Infectious Diseases (ESCMID) recommend active
screening cultures just for controlling the outbreaks,
not for endemic situations [33]. The lack of evidence
about the best anatomic site for culturing and a low
sensitivity of the surveillance tools to identify the car-
riers have been arguments against routine screening
[34]. However, a study that employed a Monte Carlo
model to assess the impact of active surveillance of A.
baumannii on patient outcomes revealed that it re-
duced transmissions and was cost-saving when A.
baumannii prevalence was at least 2% and the screen-
ing test sensitivity was 55% or higher [35]. Our ex-
perience reinforces what other authors have also
addressed: to eradicate or significantly reduce the in-
cidence in an endemic situation, screening cultures
are a must.
The skin is known to be a relevant reservoir of A. bau-
mannii, and skin samples are frequently included in the
active surveillance. Our program did not, and this could
constitute a limitation of the program. There is no inter-
national consensus on the samples to be taken in the
surveillance study of MDR-Ab. The guidelines of the
ESCMID [33] recommend: “stool samples or swab sam-
ples from the rectum or perirectal area as well as sam-
ples from the inguinal area and manipulated sites, e.g.
catheters and areas of broken skin such as wounds”,
while the HICPAC/CDC guidelines recommend taking
active screening cultures for MDR-gramnegative bacilli
from areas of skin breakdown and draining wounds and,
if a respiratory tract reservoir is suspected, from endo-
tracheal tube aspirates or sputum [15]. In this open sce-
nario, we chose two specimens, pharyngeal and rectal
swabs, because: a) respiratory colonization and infection
was the most frequently caused by A. baumannii among
our patients; b) the sensitivity of the rectal/perianal sam-
ples can achieve a 78% (higher than the sensitivity of
other localizations, as skin or wounds) [36] and the com-
bination of pharyngeal and rectal sites can achieve a sen-
sitivity of 96% [37]; c) several studies have related the
rectal colonization by MDR-Ab with a higher risk of in-
fection caused by this microorganism [38, 39]. Further-
more, assuming that the absence of skin screening
cultures could be a limitation of the study, it did not
preclude the goal of eradicating clinical colonization and
infection by MDR-Ab.
Antimicrobial stewardship was another cornerstone
of the intervention. Although some infection control
programs succeeded without any specific antibiotic
policy [25, 27], many others find it crucial [32, 40].
As occurs with other components of the bundles, this
measure needs to be adapted to the local scenario. In
our case, antibiotic pressure was likely the responsible
of the XDR-Ab outbreak. A careful analysis revealed
that the inappropriate duration of antimicrobial treat-
ments and the overuse of carbapenems needed to be
addressed to control either the spread of A. bauman-
nii or the emergence of other MDR rods.
In our opinion, the main strengths in the design of this
study are the prospective data collection and the time-
series analysis, which allows the most accurate analysis
in non-randomized intervention studies. This kind of
analysis, as well as previous data sustaining the
employed measures and no previous reports about the
spontaneous disappearance of an endemic A. baumannii,
supports the effectiveness of the presented program. On
the other hand, another key factor on the tackling of this
endemic situation was the multifaceted program, which
reinforces our idea that a multidisciplinary and transver-
sal team is necessary to achieve a more complete evalu-
ation of a system of endemism, obtaining a more
effective solution for a better care of patients. However,
the study has also some limitations. Firstly, the design of
a multifaceted program prevents us from knowing if any
of the employed measures could be futile, given that all
were made simultaneously, or if adding any other meas-
ure (as discussed previously for skin screening cultures)
would have produced the eradication of MDR-Ab earl-
ier. Secondly, although the present study reports data
from the whole hospital, many interventions were made
specifically in the ICU; thus, the extrapolation of these
measures to other kind of units may require an adapta-
tion. And finally, there are some issues with the suscep-
tibility testing. It was not complete for all the antibiotics
in all the isolates; hence, the classification as MDR/
XDR/PDR relied in a number of them on the local epi-
demiology and the susceptibility to the main drugs. Add-
itionally, the susceptibility to colistin was performed by
E-test. In 2016, few months before the study period
ended, EUCAST gave “warning” for using E-test to study
the susceptibility to colistin [41], due to a risk of false
susceptible results up to 32% [42]. We just started to use
other susceptibility test methods after the study period.
However, a possible misclassification of some isolates as
“colistin-susceptible” would not modify the main results
of the study.
Conclusions
The multicomponent intervention program performed
by a multidisciplinary team has been effective to con-
trol the XDR-Ab outbreak and to eradicate the en-
demic MDR-Ab in our hospital.
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